# GLS Ventures

> GLS Ventures is a VC fund in Sugar Land backing Medical, Health Care and Biotechnology. See 2 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Sugar Land, United States
- Total investments: 2
- Last investment: Apr 2015
- Lead investor: 0%
- Last updated: Aug 2026

GLS Ventures is a VC fund in Sugar Land focused on Medical and Health Care. GLS Ventures

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 50% |
| Health Care | 1 | 50% |
| Biotechnology | 1 | 50% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 1 | 50% |
| Funding Round | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nabriva Therapeutics | Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic forcommunity-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. | $120M | Series B | Apr 07, 2015 |  |
| Nabriva Therapeutics | Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin injection, lefamulin tablets), the first systemic pleuromutilin antibiotic forcommunity-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. | $16.5M |  | Oct 28, 2009 |  |

2 of 2 investments shown.

## Co-investors
- [Novartis Venture Fund](https://shizune.co/investors/profile/novartis-venture-fund) — VC Fund, 2 deals together
- [Wellcome Trust](https://shizune.co/investors/profile/wellcome-trust) — VC Fund, 2 deals together
- [Boxer Capital](https://shizune.co/investors/profile/boxer-capital) — VC Fund, 1 deal together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 1 deal together
- [HBM Healthcare Investments](https://shizune.co/investors/profile/hbm-healthcare-investments-ag) — VC Fund, 1 deal together
- [HBM Partners](https://shizune.co/investors/profile/hbm-partners) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

### Similar country
- [Speedinvest](https://shizune.co/investors/profile/speedinvest) — VC Fund
- [tecnet equity](https://shizune.co/investors/profile/tecnet-equity) — VC Fund
- [aws Gründungsfonds](https://shizune.co/investors/profile/aws-grnderfonds) — VC Fund

## Featured in investor lists
- [Medical VC Funds in Austria](https://shizune.co/investors/medical-vc-funds-austria)
- [Biotechnology VC Funds in Austria](https://shizune.co/investors/biotechnology-vc-funds-austria)
- [Health Care VC Funds in Austria](https://shizune.co/investors/health-care-vc-funds-austria)
- [Biotech Investors in Austria](https://shizune.co/investors/biotech-investors-austria)
- [Biotech VC Funds in Austria](https://shizune.co/investors/biotech-vc-funds-austria)

## FAQ

### What does GLS Ventures invest in?

GLS Ventures invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Austria. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did GLS Ventures last invest?

The most recent investment recorded for GLS Ventures closed in Apr 2015. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co